MVRIX CEO Sang Won Jung and CTO Dae-hyuk Kweon attended BIO-Europe 2025, held in Vienna from November 3–5.

At this event, we held active discussions with various global companies focusing on the Navibody platform and our flagship pipeline, the in vivo CAR-T therapy MIC-001.

We were able to confirm the high level of interest in precision target delivery technology, and we expect these meetings to lead to meaningful cooperation opportunities.